Have a feature idea you'd love to see implemented?
Let us know!
FATE Fate Therapeutics Inc
Price (delayed)
$2.595
Market cap
$295.51M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.71
Enterprise value
$343.98M
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture
Highlights
FATE's EPS is up by 21% year-on-year and by 11% since the previous quarter
The net income has grown by 17% YoY and by 8% from the previous quarter
FATE's revenue has surged by 90% since the previous quarter but it has dropped by 90% year-on-year
The gross profit has surged by 90% since the previous quarter but it has dropped by 90% year-on-year
The company's equity fell by 9% YoY and by 7% QoQ
Key stats
What are the main financial stats of FATE
Market
Valuations
Earnings
Shares outstanding
113.88M
Market cap
$295.51M
Enterprise value
$343.98M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.74
Price to sales (P/S)
24.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.93
Revenue
$12.32M
EBIT
-$175.72M
EBITDA
-$156.56M
Free cash flow
-$141.45M
Per share
Balance sheet
Liquidity
EPS
-$1.71
Free cash flow per share
-$1.2
Book value per share
$3.49
Revenue per share
$0.1
TBVPS
$4.5
Total assets
$528.82M
Total liabilities
$131.84M
Debt
$100.56M
Equity
$396.98M
Working capital
$284.6M
Debt to equity
0.25
Current ratio
9.18
Quick ratio
9.23
Net debt/EBITDA
-0.31
Margins
Efficiency
Dividend
EBITDA margin
-1,271.1%
Gross margin
100%
Net margin
-1,426.7%
Operating margin
-1,587.3%
Return on assets
-32.7%
Return on equity
-44.1%
Return on invested capital
-33.4%
Return on capital employed
-35.6%
Return on sales
-1,426.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FATE stock price
How has the Fate Therapeutics stock price performed over time
Intraday
-4.6%
1 week
-14.36%
1 month
-25.86%
1 year
50%
YTD
-30.61%
QTD
-25.86%
Financial performance
How have Fate Therapeutics's revenue and profit performed over time
Revenue
$12.32M
Gross profit
$12.32M
Operating income
-$195.51M
Net income
-$175.72M
Gross margin
100%
Net margin
-1,426.7%
FATE's revenue has surged by 90% since the previous quarter but it has dropped by 90% year-on-year
The gross profit has surged by 90% since the previous quarter but it has dropped by 90% year-on-year
The operating margin has soared by 52% from the previous quarter
The net margin has surged by 51% since the previous quarter
Growth
What is Fate Therapeutics's growth rate over time
Valuation
What is Fate Therapeutics stock price valuation
P/E
N/A
P/B
0.74
P/S
24.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.93
FATE's EPS is up by 21% year-on-year and by 11% since the previous quarter
FATE's price to book (P/B) is 86% lower than its 5-year quarterly average of 5.7 and 22% lower than its last 4 quarters average of 1.0
The company's equity fell by 9% YoY and by 7% QoQ
FATE's revenue has surged by 90% since the previous quarter but it has dropped by 90% year-on-year
The stock's price to sales (P/S) is 72% less than its 5-year quarterly average of 93.7 and 32% less than its last 4 quarters average of 38.4
Efficiency
How efficient is Fate Therapeutics business performance
FATE's return on sales has surged by 51% since the previous quarter
The ROIC has grown by 6% from the previous quarter
Fate Therapeutics's return on assets has increased by 5% QoQ but it has decreased by 3.2% YoY
The ROE has grown by 5% from the previous quarter
Dividends
What is FATE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FATE.
Financial health
How did Fate Therapeutics financials performed over time
The total liabilities has contracted by 10% YoY and by 8% from the previous quarter
FATE's total assets is down by 10% year-on-year and by 7% since the previous quarter
The debt is 75% smaller than the equity
The company's equity fell by 9% YoY and by 7% QoQ
The debt has declined by 5% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.